IBD treatment and frailty in patients over 60
Part of Digestive system clinical trials.
This study looks at how inflammatory bowel disease (IBD) activity affects frailty in people over 60. It tests whether starting or changing medication for active IBD can help understand and manage frailty.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 60 years or older.
- You must have Crohn's disease or ulcerative colitis (confirmed by a doctor).
- You need to start a new medication (like oral mesalazine, steroids, immunosuppressants, or biologics) because your IBD is active.
- Your IBD activity must be shown by symptoms or lab tests (like high fecal calprotectin or C-reactive protein).
- You cannot have an ostomy (a bag for waste).
- You cannot change medication only because of side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the immune system ages in people over 60 with inflammatory bowel disease (IBD) and how well newer treatments work for them. It aims to find out if immune aging affects treatment success.
This trial looks at people with Crohn's disease or ulcerative colitis who have already tried and failed at least one advanced medication (like a biologic or small molecule drug). If you are starting a new advanced therapy, researchers will track how well it works for you.
This study tests whether adding a diet and stress management program to standard advanced therapy helps people with active Crohn's disease or ulcerative colitis feel better. It combines lifestyle changes with new medications to improve treatment outcomes.
This study follows people with inflammatory bowel disease (Crohn's disease or ulcerative colitis) who may be taking immunosuppressants (medicines that calm the immune system). Researchers will track how the disease progresses and look at factors like gut bacteria to find ways to predict complications.
This study looks at how fats in your blood and gut lining change in inflammatory bowel disease (IBD). It might help doctors understand IBD better and could lead to better treatments.
This study tests whether it is safe to stop taking acid-reducing pills (PPIs) for people with inactive IBD. If you have been on a PPI for over 6 months and your IBD is stable, you may be able to join.
Hear when a new IBD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.